Department of Biomedical Science, Hallym University, Chuncheon, Korea.
Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Korea. ; Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea.
Gut Liver. 2014 Mar;8(2):131-9. doi: 10.5009/gnl.2014.8.2.131. Epub 2014 Mar 11.
Gastric cancer is the second most common cause of cancer-related death in the world. A growing body of evidence indicates that inflammation is closely associated with the initiation, progression, and metastasis of many tumors, including those of gastric cancer. In addition, approximately 60% of the world's population is colonized by Helicobacter pylori, which accounts for more than 50% of gastric cancers. While the role of inflammation in intestinal and colonic cancers is relatively well defined, its role in stomach neoplasia is still unclear because of the limited access of pathogens to the acidic environment and the technical difficulties isolating and characterizing immune cells in the stomach, especially in animal models. In this review, we will provide recent updates addressing how inflammation is involved in gastric malignancies, and what immune characteristics regulate the pathogenesis of stomach cancer. Also, we will discuss potential therapeutics that target the immune system for the efficient treatment of gastric cancer.
胃癌是全球癌症相关死亡的第二大主要原因。越来越多的证据表明,炎症与许多肿瘤的发生、发展和转移密切相关,包括胃癌。此外,世界上大约 60%的人口被幽门螺杆菌定植,这占了超过 50%的胃癌病例。虽然炎症在肠道和结直肠癌中的作用相对明确,但由于病原体进入酸性环境的通道有限以及在胃部分离和鉴定免疫细胞的技术困难,尤其是在动物模型中,其在胃肿瘤发生中的作用仍不清楚。在这篇综述中,我们将提供最新的研究进展,阐述炎症如何参与胃癌的发生,以及哪些免疫特征调节胃癌的发病机制。此外,我们还将讨论针对免疫系统的潜在治疗方法,以有效治疗胃癌。